Clinical Trials
9 trialsNCT03041701 2022-04-14
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00677287 2009-12-29
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer
Tokyo University
Phase 1/2 Terminated
NCT00677326 2009-12-29
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer
Tokyo University
Phase 1/2 Terminated
NCT00677612 2009-12-29
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer
Tokyo University
Phase 1/2 Terminated
NCT00681252 2009-11-19
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer
Tokyo University
Phase 1/2 Completed
NCT00681421 2009-11-19
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer
Tokyo University
Phase 1/2 Completed
NCT00681577 2009-11-19
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer
Tokyo University
Phase 1/2 Completed
NCT00683358 2009-05-07
Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
Tokyo University
Phase 1/2 Unknown
NCT00673777 2008-05-14
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer
Tokyo University
Phase 1/2 Unknown